Open AccessProteinase-activated receptor 1 antagonism ameliorates experimental pulmonary hypertension
Author(s) -
Yukimitsu Kuwabara,
Mariko Tanaka-Ishikawa,
Kohtaro Abe,
Mayumi Hirano,
Yoshitaka Hirooka,
Hiroyuki Tsutsui,
Kenji Sunagawa,
Katsuya Hirano
Publication year - 2018
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1093/cvr/cvy284
Subject(s) - antagonism , pulmonary hypertension , receptor , pharmacology , medicine , cardiology , chemistry
Pulmonary hypertension (PH) is characterized by progressive increases in pulmonary vascular resistance (PVR). Thrombotic lesions are common pathological findings. The pulmonary artery has a unique property regarding the vasoconstrictive response to thrombin, which is mediated by proteinase-activated receptor 1 (PAR1). We aim to elucidate the role of PAR1 in the development and progression of PH.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom